These results demonstrate that the anti-tumor activity of Dll4 blockade in the RP-R-01 RCC model is entirely dependent on targeting Dll4 in the tumor stroma as opposed to tumor cell-expressed Dll4, and furthermore highlights the lack of tumor growth-promoting autocrine Dll4-Notch tumor cell signaling in this model. This evidence concerns the gene DLL4 and renal cell carcinoma.